These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Risk factors for systemic reactions to allergen-specific subcutaneous immunotherapy. Iglesias-Cadarso A; Hernández-Weigand P; Reaño M; Pérez-Pimiento A; Vargas Núñez JA; de la Torre F J Investig Allergol Clin Immunol; 2010; 20(7):621-2. PubMed ID: 21314007 [No Abstract] [Full Text] [Related]
3. Current status of allergen immunotherapy (hyposensitization). Report of a WHO/IUIS working Group. Allerg Immunol (Leipz); 1989; 35(4):235-47. PubMed ID: 2696375 [No Abstract] [Full Text] [Related]
4. The current status of allergen immunotherapy (hyposensitisation). Report of a WHO/IUIS working group. Allergy; 1989 Aug; 44(6):369-79. PubMed ID: 2679219 [No Abstract] [Full Text] [Related]
5. Oral routes for immunotherapy: clinical efficacy and kinetics of the allergen. Canonica GW; Passalacqua G; Mariani G; Motta C; Bartolomei M; Mistrello G; Falagiani P; Bagnasco M Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1997; (91):56-64; discussion 64-7. PubMed ID: 9383892 [No Abstract] [Full Text] [Related]
6. Current status of allergen immunotherapy (hyposensitization): memorandum from a WHO/IUIS meeting. Bull World Health Organ; 1989; 67(3):263-72. PubMed ID: 2670296 [TBL] [Abstract][Full Text] [Related]
7. Specific immunotherapy by different allergen applications: subcutaneous, sublingual, oral or rectal administration and lymph node injection. Kleine-Tebbe J Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():87-95; discussion 95. PubMed ID: 20799448 [No Abstract] [Full Text] [Related]
8. Different methods of local allergen-specific immunotherapy. Kägi MK; Wüthrich B Allergy; 2002 May; 57(5):379-88. PubMed ID: 11972476 [No Abstract] [Full Text] [Related]
9. Oral immunotherapy: a way forward? Platts-Mills TA J Allergy Clin Immunol; 1987 Aug; 80(2):129-32. PubMed ID: 2956315 [No Abstract] [Full Text] [Related]
11. The history of sublingual immunotherapy. Pajno GB; Barberi S Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):1-3. PubMed ID: 19944001 [TBL] [Abstract][Full Text] [Related]
12. New routes and formulations for allergen-specific immunotherapy. Wheeler AW; Drachenberg KJ Allergy; 1997 Jun; 52(6):602-12. PubMed ID: 9226053 [No Abstract] [Full Text] [Related]
13. Immunological mechanisms of allergen-specific immunotherapy. Larché M; Akdis CA; Valenta R Nat Rev Immunol; 2006 Oct; 6(10):761-71. PubMed ID: 16998509 [TBL] [Abstract][Full Text] [Related]
14. Allergen-specific immunotherapy: current concepts and future directions. Bieber T; Simon HU Allergy; 2011 Jun; 66(6):709-12. PubMed ID: 21518373 [No Abstract] [Full Text] [Related]
15. What is the factor that improves adherence to allergen-specific immunotherapy? A secretary! Lombardi C Ann Allergy Asthma Immunol; 2015 Jun; 114(6):530-1. PubMed ID: 25863450 [No Abstract] [Full Text] [Related]
17. [Specific immunotherapy: indications and contraindications]. Reinhardt MC Rev Med Suisse Romande; 1994 Mar; 114(3):233-43. PubMed ID: 8171233 [No Abstract] [Full Text] [Related]
18. Current status of allergen immunotherapy. Shortened version of a World Health Organisation/International Union of Immunological Societies Working Group Report. Lancet; 1989 Feb; 1(8632):259-61. PubMed ID: 2563421 [No Abstract] [Full Text] [Related]